ClinicalTrials.gg

Program

Peptide-drug Conjugate BL0020

Its studies are mostly in Small Cell Lung Carcinoma, led by Shanghai Best-Link Bioscience.

Furthest: phase 2, since Feb 9, 20263 company-led studies, 3 open or runningNext primary completion: Dec 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Best-Link Bioscience33 open or runningphase 2since Feb 9, 2026May 24, 2023Dec 22, 2027phase 2 · NCT07414927

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 24, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05886868 · 66 planned · Australia, China
  2. Feb 9, 2026Phase 2 study in Small Cell Lung CarcinomaPhase 2 reachedNCT07414927 · 48 planned · China
  3. Apr 20, 2026Phase 1 study in Small Cell Lung CarcinomaNCT07550842 · 33 planned · China

Ahead

  1. Dec 22, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07414927
  2. Apr 28, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07550842

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07550842Small Cell Lung Carcinoma · China1Not yet recruitingApr 28, 202833
NCT07414927Small Cell Lung Carcinoma · China2Not yet recruitingDec 22, 202748
NCT05886868Advanced Solid Tumor · Australia, China1RecruitingJul 202466

How it is read

Names in the registry

  • “BL0020”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.